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Abstract
Introduction: Wilson disease (WD) is an inherited disorder of human copper metabolism, characterised by
accumulation of copper predominantly in the liver and brain, leading to severe hepatic and neurological disease.
Interesting findings in animal models of WD (Atp7b
-/- and LEC rats) showed altered lipid metabolism with a
decrease in the amount of triglycerides and cholesterol in the serum. However, serum lipid profile has not been
investigated in large human WD patient cohorts to date.
Patients and Methods: This cohort study involved 251 patients examined at the Heidelberg and Dresden
(Germany) University Hospitals. Patients were analysed on routine follow-up examinations for serum lipid profile,
including triglycerides, cholesterol, high density lipoprotein (HDL) and low density lipoprotein (LDL). Data on these
parameters at time of diagnosis were retrieved by chart review where available. For statistical testing, patients were
subgrouped by sex, manifestation (hepatic, neurological, mixed and asymptomatic) and treatment (D-penicillamine,
trientine, zinc or combination).
Results: A significant difference in total serum cholesterol was found in patients with hepatic symptoms, which
diminished under therapy. No alterations were observed for HDL, LDL and triglycerides.
Conclusion: Contradictory to previous reports using WD animal models (Atp7b
-/- and LEC rats), the most obvious
alteration in our cohort was a lower serum cholesterol level in hepatic-affected patients, which might be related to
liver injury. Our data suggested unimpaired cholesterol metabolism in Wilson disease under therapy, independent
of the applied medical treatment.
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Background
Wilson disease (WD) is an autosomal recessive inherited
disorder of copper metabolism caused by mutations of
the hepatic copper transporting ATPase ATP7B, which
facilitates biliary copper excretion. Thus ATP7B dys-
function leads to toxic copper accumulation in the liver
and other tissues, most notably the central nervous sys-
tem [1,2]. The genetic background of the disease is
highly variable with more than 300 ATP7B mutations
known so far [3-5]. Liver injury is the most common
manifestation of Wilson disease and it ranges from stea-
tosis hepatis to irreversible liver cirrhosis and fulminant
liver failure [6,7] with a variable age at onset [8]. The
liver is not only responsible for maintenance of copper
homoestasis but plays a central role in lipid transport
and metabolism. Thus liver disease can be associated
with profound and characteristic changes in lipoprotein
composition, metabolism and transport [9]. However,
alterations of lipid metabolism in humans with copper
overload disease have not been investigated in larger
cohorts so far.
Here, some data are available for rodent models of
WD, the Atp7b
-/- mouse and the LEC rat. Atp7b knock-
out mice exhibit down-regulated lipid metabolism [10].
A significant decrease in the amount of triglycerides and
cholesterol was detected, whereas LDL cholesterol
remained unchanged [10]. Very low density lipoprotein
(VLDL) fraction was the most affected, showing a
3.6-fold reduction in cholesterol concentration. Analysis
of liver tissue revealed that cholesterol was indeed mark-
edly decreased [10]. In contrast, Levy et al. showed an
increased content of triglycerides, free cholesterol and
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any medium, provided the original work is properly cited.cholesteryl ester in the liver of LEC rats. This steatosis
was associated with hypotriglyceridemia, hypocholesteri-
nemia and abnormalities in both circulating lipoprotein
composition and size [11]. In both animal models of
Atp7b
-/- mice and LEC rats, there is a significant effect
of accumulated copper on hepatic HMG-CoA reductase
(the rate limiting enzyme in de novo cholesterol bio-
synthesis). HMG-CoA reductase mRNA levels were
most significantly down-regulated in Atp7b
-/- mice [10]
while the activity of the enzyme was decreased in LEC
rats [11].
Several other animal studies support the idea that lipid
and copper metabolism are linked. For example, copper
deficient rats showed elevated total cholesterol and tri-
glyceride plasma levels and a significant decrease in
hepatic total cholesterol [12]. HMG-CoA reductase was
elevated two-fold with copper deficiency [12,13]. In
male Wistar rats, Galhardi et al. showed reduced choles-
terol and triglycerides, total cholesterol and LDL in the
serum after dietary copper supplementation. However,
there was no significant change in final body weight and
high-density lipoprotein [13,14].
There are limited data regarding Wilson disease and
the alteration of lipid metabolism in humans. Brewer et
al. demonstrated in eleven female and thirteen male
WD patients that zinc treatment reduced cholesterol
levels by about 10% in both sexes and reduced HDL
cholesterol level by about 20% in male patients [15].
Rodo et al. investigated 45 WD individuals treated with
D-pencillamine or zinc sulphate and demonstrated sig-
nificantly lower levels of cholesterol, LDL cholesterol
and Vitamin E compared with untreated healthy con-
trols. No differences were seen in triglyceride levels
between both groups [16].
These findings were in line with other smaller series
in healthy male individuals that evaluated the role of
zinc in lipid reducing therapy [17-19]. Black et al. exam-
ined the effect of oral zinc supplementation for twelve
weeks in thirty one healthy men (9 subjects in the pla-
cebo group, 13 in the 50mg Zn/d group and 9 in the 75
mg Zn/d group) in a double blinded study [19]. No
changes in total serum cholesterol, LDL, VLDL and tri-
glycerides were observed. Hooper et al. showed a 25%
decrease below baseline values of HDL in 12 healthy
men after zinc supplementation [17]. Total cholesterol,
triglycerides and LDL cholesterol levels did not change.
Similar data were revealed by Chandra in 11 healthy
men: HDL concentration decreased significantly and
LDL increased slightly after ingestion of elemental zinc
[18]. The mechanism of these effects of zinc on choles-
terol metabolism is currently unclear. The aim of the
current study was to assess lipid metabolism parameters
in patients with Wilson disease at initial presentation
and in course under medical therapy.
Results
Findings at initial presentation
In untreated Wilson disease, median serum cholesterol
and triglycerides presented within the normal range. A
comparison between male and female patients showed no
significant differences concerning serum lipids (Table 1).
For further analysis, patients were subgrouped by pre-
sentation (neurologic, hepatic, mixed and asympto-
matic). As expected, patients with hepatic manifestation
showed higher levels of liver function tests namely ala-
nine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST), bilirubin and lower levels of serum
albumin. Total cholesterol was lower in patients with
hepatic symptoms (Figure 1) while no alterations in the
other analysed parameters of lipid metabolism were
noted (Table 2).
Course under medical treatment
Under at least 2 years of therapy, the differences within
LFTs (ALT, AST) diminished, reflecting the hepatic
response to medical treatment. With improvement of
liver function, parameters of lipid metabolism - in parti-
cular cholesterol levels - were comparable between
patients, independent of initial presentation (Table 3).
Moreover, it was noticeable that lipoprotein a, an inde-
pendent risk factor for atherosclerosis, was significantly
decreased in those individuals with hepatic and mixed
presentation.
To evaluate the influence of different treatment regi-
mens, data for patients under therapy were analysed by
treatment (Table 4). For cholesterol and serum lipids,
no statistically significant differences were observed
between the groups. Under zinc and combination treat-
ment, significantly higher levels of lipase and amylase,
known side effects of the medication, were observed.
Discussion
The liver is a central organ in lipid transport and metabo-
lism. It is well known that liver diseases are associated with
profound and characteristic changes in lipoprotein compo-
sition and metabolism [9]. Only limited data are currently
available on the detailed lipoprotein alterations in Wilson
d i s e a s e .T h ea i mo ft h ec u r r e n ts t u d yw a st oi n v e s t i g a t e
alterations in lipid metabolism parameters in WD patients.
The study examined 251 Wilson disease patients. Our
expectation with regard to animal models was to show
altered parameters of lipid metabolism. Despite the fact
that differences in VLDL were a major finding in the
rodent studies [10] we focused on the lipid parameters
assessed in clinical routine to follow WD patients. This
represents a limitation of our study.
While Atp7b knockout mice showed down-regulated
lipid metabolism with a significant decrease in the
amount of triglycerides and cholesterol [11,13], in our
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Page 2 of 6Table 1 A comparison between treatment naive male and female patients showed no significant differences
concerning serum lipids
n
m:f
Limits of normal Total Male Female p-value
ALT 139 55:84 f: -35 U/l
m: -50 U/l
62.3
(7-3743)
95
(7-3743)
54
(7-472)
0.032
AST 135 55:80 f: -35 U/l
m: -50 U/l
51.9
(6-2106)
52
(6-2106)
50
(13-323)
0.485
Bilirubin 122 44:78 < 1,0 mg/dl 0.9
(0.1-39)
0.9
(0.2-23)
0.9
(0.1-39)
0.974
Albumin 103 37:66 30-50 g/l 43
(23-57)
43.9
(25-55)
42.6
(23-57)
0.179
TG 64 26:38 < 150 mg/dl 114
(33-888)
149.5
(59-313)
106.5
(33-888)
0.061
Cholesterol 70 27:43 < 200 mg/dl 175.5
(66-319)
186
(93-319)
170
(66-294)
0.436
HDL 14 7:7 f: >50 mg/dl m: >40 mg/dl 56.5
(42-77)
53
(42-67)
57 (48-77) 0.179
LDL 12 7:5 < 160 mg/dl 96
(63-218)
97
(63-218)
95
(63-166)
0.935
BMI 26 12:14 18.5-25
kg/m²
22.1
(14.8-30.8)
22.9
(15.3-27.7)
21.2
(14.8-30.8)
0.877
No differences were demonstrated between both sexes in the lipid metabolism parameters.
Figure 1 Serum cholesterol subgrouped by presentation at initial presentation (n = 70). Median total serum cholesterol was reduced in
hepatic patients (p = 0.004).
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ides presented within the normal range. A lower median
cholesterol was only evident in the subgroup of patients
with hepatic symptoms. Whether this finding is a specific
effect of the copper overload or just an epiphenomenon
of liver injury remains open, as previous studies observed
a clear trend towards low levels of total cholesterol in
patients chronic liver disease [9]. All other analysed para-
meters of lipid metabolism were inconspicuous even in
the hepatic patients. In further course under therapy the
finding of lower cholesterol in patients with hepatic pre-
sentation was no longer evident. After two years of treat-
ment the analyzed lipid metabolism parameters were
comparable between patients, independent of the initial
presentation.
To evaluate the influence of different treatment regi-
mens, data were also analysed by treatment. For choles-
terol and serum lipids, no statistically significant
Table 2 Baseline parameters of treatment naive patients subgrouped by different manifestation revealed a significant
decrease in cholesterol in hepatic patients
n Limits of normal Hepatic Neurological Mixed Asymptomatic p-value
ALT 139 f: -35 U/l
m: -50 U/l
101.9
(7-3743)
22
(10-140)
28.2 (17-272) 20
(7-168)
>0.001
AST 135 f: -35 U/l
m: -50 U/l
76.9
(13-2106)
21.2
(6-58)
32
(19-108)
26.4
(11-102)
>0.001
Bilirubin 122 < 1.0 mg/dl 1.1
(0.2-39)
0.9
(0.1-3.8)
0.6
(0.2-1.4)
0.5
(0.2-0.9)
0.009
Albumin 103 30-50 g/l 41
(23-55)
45.2
(38-52)
43
(35-57)
46.3
(35-52)
0.001
TG 64 < 150 mg/dl 110
(33-888)
120
(63-200)
124
(40-249)
60
(59-100)
0.300
Cholesterol 70 < 200 mg/dl 158
(66-319)
194
(123-243)
186
(145-244)
195
(173-294)
0.004
HDL 14 >50 mg/dl 57
(42-76)
53
(48-77)
60
(56-64)
- 0.923
LDL 12 < 160 mg/dl 96
(63-218)
161
(156-166)
88
(81-95)
- 0.207
BMI 26 18.5-25 kg/m² 20.6
(14.9-24.5)
26.2
(20.3-30.8)
23.1
(14.8-28.6)
19.7
(19.7-19.7)
0.126
Median serum cholesterol and triglycerides presented within normal range.
Table 3 Parameters of lipid metabolism of Wilson disease patients under therapy
n Limits of normal Hepatic Neurological Mixed Asymptomatic p-value
ALT 249 f: -35 U/l
m: -50 U/l
41
(10-3743)
25
(11-70)
30
(13-99)
24.5
(8-78)
<0.001
AST 250 f: -35 U/l
m: -50 U/l
29
(12-2106)
23
(10-102)
27.9 (12-79) 20
(11-77)
<0.001
Bilirubin 239 < 1.0 mg/dl 0.7
(0.2-23.0)
0.6
(0.2-2.7)
0.7
(0.2-4.5)
0.6
(0.3-1.9)
0.001
Albumin 231 30-50 g/l 44
(21-55)
44.4
(28-56)
44
(30-73)
45.6
(37-54)
0.277
TG 247 < 150 mg/dl 100
(28-888)
95
(29-438)
106.5
(12-221)
93
(29-285)
0.588
Cholesterol 248 < 200 mg/dl 179.5
(90-319)
182
(120-365)
183
(113-273)
188.5
(103-265)
0.780
HDL 124 >50 mg/dl 55
(27-113)
53
(32-103)
57.5
(40-81)
57
(36-84)
0.588
LDL 115 < 160 mg/dl 108
(43-218)
96
(63-229)
98.5
(63-159)
113.5
(74-156)
0.781
Lp(a) 61 < 25 mg/dl 4.8
(5-52.5)
21.4
(4.8-48.5)
4.9
(4.8-55.4)
20.5
(4.8-38.9)
0.016
BMI 166 18.5-25 kg/m² 22.8
(14.2-41.1)
22.1
(17.7-33.7)
23.8
(15.1-32.5)
22.1
(18.7-28.1)
0.839
With improvement of liver function, parameters of lipid metabolism were comparable between patients, independent of initial presentation.
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regimes. Thus, in our cohort we could not verify the
previous observation of reduced cholesterol levels under
zinc therapy [15,16].
In summary, our study at least in part contradicts the
findings obtained in Wilson disease animal models. The
most obvious alteration was a lower serum cholesterol
level in hepatic- affected patients, which might be
related to liver injury. Our data suggested an unim-
paired cholesterol metabolism in Wilson disease under
therapy, regardless of the applied treatment regimen.
Material and methods
Patients
This cohort study involved 251 patients with an estab-
lished diagnosis of Wilson disease examined at the Uni-
versity Hospitals of Heidelberg and Dresden between
1998 and 2009. The study protocol was a priori approved
by the ethical committee of the University of Heidelberg.
The diagnosis of this disease was based on the critieria
of the 8
th International Conference of Wilson disease
and Menkes disease [20]. Patients with uncertain diag-
n o s i sw e r ee x c l u d e da sd e s c r ibed previously [21]. In
terms of a cross sectional study, all patients were ana-
lysed on routine follow-up examinations for serum lipid
profile, including triglycerides, cholesterol, HDL and
LDL. Data on serum lipids at time of diagnosis were
retrieved by chart review and were not available for all
cases. For statistical testing, they were subgrouped by
treatment (d-penicillamine, trientine, zinc and combina-
tion), sex and manifestation (hepatic, neurological,
mixed and asymptomatic). P-values were retrieved using
Mann-Whitney or Kruskal-Wallis test.
Statistical methods
A p-value less than 0.05 was considered significant. Cal-
culation was carried out using SPSS™ for Windows™
Software V15.0.
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